101 related articles for article (PubMed ID: 17897880)
21. Rational live oral carrier vaccine design by mutating virulence-associated genes of Yersinia enterocolitica.
Igwe EI; Rüssmann H; Roggenkamp A; Noll A; Autenrieth IB; Heesemann J
Infect Immun; 1999 Oct; 67(10):5500-7. PubMed ID: 10496939
[TBL] [Abstract][Full Text] [Related]
22. Yersinia outer proteins: Yops.
Trosky JE; Liverman AD; Orth K
Cell Microbiol; 2008 Mar; 10(3):557-65. PubMed ID: 18081726
[TBL] [Abstract][Full Text] [Related]
23. Plasmid maintenance systems suitable for GMO-based bacterial vaccines.
Spreng S; Viret JF
Vaccine; 2005 Mar; 23(17-18):2060-5. PubMed ID: 15755571
[TBL] [Abstract][Full Text] [Related]
24. Use of attenuated bacteria as delivery vectors for DNA vaccines.
Daudel D; Weidinger G; Spreng S
Expert Rev Vaccines; 2007 Feb; 6(1):97-110. PubMed ID: 17280482
[TBL] [Abstract][Full Text] [Related]
25. Engineering secretable forms of chaperones for immune modulation and vaccine development.
Beachy SH; Kisailus AJ; Repasky EA; Subjeck JR; Wang XY; Kazim AL
Methods; 2007 Nov; 43(3):184-93. PubMed ID: 17920514
[TBL] [Abstract][Full Text] [Related]
26. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods.
Lundgren A; Kaim J; Jertborn M
Vaccine; 2009 Jul; 27(33):4529-36. PubMed ID: 19446596
[TBL] [Abstract][Full Text] [Related]
27. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
Khan AA; Babu JP; Gupta G; Rao DN
Vaccine; 2008 Jan; 26(3):316-32. PubMed ID: 18096277
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins.
Husseiny MI; Hensel M
Vaccine; 2009 Jun; 27(28):3780-7. PubMed ID: 19464562
[TBL] [Abstract][Full Text] [Related]
29. Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses.
Schroeder J; Aebischer T
Vaccine; 2009 Nov; 27(48):6748-54. PubMed ID: 19748581
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: potential application in vaccine and therapeutical developments.
Chamekh M
Immunopharmacol Immunotoxicol; 2010 Mar; 32(1):1-4. PubMed ID: 19778176
[TBL] [Abstract][Full Text] [Related]
31. Particle-based vaccines for transcutaneous vaccination.
Combadière B; Mahé B
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):293-315. PubMed ID: 17915323
[TBL] [Abstract][Full Text] [Related]
32. Induction of a protective immune response against swine Chlamydophila abortus infection in mice following co-vaccination of omp-1 DNA with recombinant MOMP.
Zhang F; Li S; Yang J; Yang L; He C
Zoonoses Public Health; 2009 Mar; 56(2):71-6. PubMed ID: 18721226
[TBL] [Abstract][Full Text] [Related]
33. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
[TBL] [Abstract][Full Text] [Related]
34. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus.
Li X; Liu R; Tang H; Jin M; Chen H; Qian P
Vaccine; 2008 May; 26(22):2714-22. PubMed ID: 18436351
[TBL] [Abstract][Full Text] [Related]
35. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
Jacobson MA; Adler SP; Sinclair E; Black D; Smith A; Chu A; Moss RB; Wloch MK
Vaccine; 2009 Mar; 27(10):1540-8. PubMed ID: 19168107
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of Yersinia pestis with deletion of lcrG, a known negative regulator for Yop secretion of type III secretion system.
Du Z; Tan Y; Yang H; Qiu J; Qin L; Wang T; Liu H; Bi Y; Song Y; Guo Z; Han Y; Zhou D; Wang X; Yang R
Int J Med Microbiol; 2009 Jun; 299(5):355-66. PubMed ID: 19109068
[TBL] [Abstract][Full Text] [Related]
37. Isolation of rifampicin resistant Flavobacterium psychrophilum strains and their potential as live attenuated vaccine candidates.
LaFrentz BR; LaPatra SE; Call DR; Cain KD
Vaccine; 2008 Oct; 26(44):5582-9. PubMed ID: 18708112
[TBL] [Abstract][Full Text] [Related]
38. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
[TBL] [Abstract][Full Text] [Related]
39. Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens.
Gentschev I; Spreng S; Sieber H; Ures J; Mollet F; Collioud A; Pearman J; Griot-Wenk ME; Fensterle J; Rapp UR; Goebel W; Rothen SA; Dietrich G
Chemotherapy; 2007; 53(3):177-80. PubMed ID: 17347563
[TBL] [Abstract][Full Text] [Related]
40. Fine-tuning the safety and immunogenicity of Listeria monocytogenes-based neonatal vaccine platforms.
Loeffler DI; Smolen K; Aplin L; Cai B; Kollmann TR
Vaccine; 2009 Feb; 27(6):919-27. PubMed ID: 19059297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
